VCO’s usage for Covid-19 is being investigated further by PCHRD.
On Tuesday, a representative of the Philippine Council for Health Research and Development (PCHRD) indicated that more research is being done on the use of virgin coconut oil (VCO) as an additional therapy for patients with coronavirus illness 2019 (Covid-19).
PCHRD Executive Director Jaime Montoya indicated in a webinar that they might be looking at inflammatory indicators to see how much inflammation patients have.
“We’ll see if the VCO can do anything to reduce or eliminate inflammatory indicators (in Covid-19 patients),” he said.
Meanwhile, Secretary of Science and Technology Fortunato de la Pea of the Department of Science and Technology (DOST) revealed that data from the VCO clinical trial at the Philippine General Hospital is still being analyzed.
He believes that more research “at the molecular level” is needed to determine the true impact of VCO in Covid-19 patients.
De la Pea, on the other hand, remarked that the trial had a positive outcome in terms of alleviating Covid-19 symptoms.
Regardless, he admitted that the difference between those who received VCO and those who did not is “not statistically significant.”
“Lagundi is already available on the market as a cough and asthma treatment. Similarly, VCO is already on store shelves (being offered) for its wide range of products, ranging from health to cosmetics. We were obliged to discover alternatives that were both accessible and affordable when the Covid-19 pandemic struck “Montoya explained.
According to Montoya, a community trial on VCO as an adjuvant therapy for Covid-19 that was undertaken in Santa Rosa, Laguna, revealed that VCO assisted study participants in reducing or completely eliminating symptoms.
“According to the findings, VCO aids in the treatment of symptoms in mild (Covid-19) cases. VCO, as a supplement, aided them (participants) in recovering faster “he stated